NOTICE
Our Presentation
Beneficial effect on intestinal growth of a long-acting GLP-2 analog, HM15912, after treatment switching from conventional GLP-2 drug or other long-acting GLP-2 analogs under clinical development in animal model
Abstract Number: SAT-028
Session: P59 - Membrane Receptors and Intracellular Signaling: Membrane Receptor Signaling, June 17, 2023, 1:00 PM - 2:00 PM CST, ENDOExpo
Presenter: In Young Choi, Ph.D. / Hanmi Pharmaceutical
HM15912, a novel long-acting GLP-2 analog, improves intestinal growth and absorption capacity in rat model of short bowel syndrome
Abstract Number: SAT-030
Session: P59 - Membrane Receptors and Intracellular Signaling: Membrane Receptor Signaling, June 17, 2023, 1:00 PM - 2:00 PM CST, ENDOExpo
Presenter: Jaehyuk Choi, Ph.D. / Hanmi Pharmaceutical
In vitro characterization of a novel long-acting glucagon analog (HM15136) and its potential effect in animal models of chronic hypoglycemic diseases
Abstract Number: SAT-149
Session: P65 - Diabetes & Vascular Disease: Hypoglycemia, June 17, 2023, 1:00 PM - 2:00 PM CST, ENDOExpo
Presenter: Jung Kuk Kim, Ph.D. / Hanmi Pharmaceutical
Amosartan
1st fixed-dose combination drug introduced in Korea
Amosartan Q
Controls Hypertension and Dyslipidemia at single treatment
Amosartan Plus
Treatment to patient not adequately controlled on agent double combo FDCs
Amosartan XQ
Controls Hypertension and Dyslipidemia at single treatment
Rosuzet
Increased efficacy due to improved lipid level control
Gugutams
A novel treatment option for ED patients accompanied by BPH
Monterizine
40% of allergic rhinitis patients accompanied by asthma , 80% of asthma patients accompanied by allergic rhinitis
Hyalrheuma injection
CE certified by SGS as a class-3 medical device
Esomezol DR
Dual release concept of Esomeprazole which can prevent NAB(Nocturnal Acid Breakthrough) symptom
